TABLE 5.
Quinoxaline | CVa | Recoveryb | LODb | LOQb |
---|---|---|---|---|
% | % | pmol/ml | pmol/ml | |
Glucosone | 6 | 109 | 6.1 | 18.3 |
1-DG | 4 | 112 | 2.2 | 6.6 |
3-DG | 5 | 97 | 5.4 | 16.2 |
Lederer's glucosone | —c | 114 | 3.5 | 10.5 |
Pentosone | 7 | 98 | 8.3 | 24.9 |
1-DP | 9 | 82 | 2.5 | 7.5 |
3-DP | 8 | 93 | 3.5 | 10.5 |
Threosone | 3 | 90 | 4.2 | 12.6 |
1-DT | 3 | 91 | 0.5 | 1.5 |
3-DT | 3 | 98 | 2.0 | 6.0 |
MGO | 8 | 106 | 3.0 | 9.0 |
GO | 9 | 98 | 6.9 | 20.7 |
Pyruvic acid | 2 | 99 | 14.1 | 42.3 |
Glyoxylic acid | 4 | 92 | 42.2 | 126.6 |
Oxalic acid | 7 | 89 | 6.8 | 20.4 |
3,4-DDP | 3 | 110 | 0.8 | 2.4 |
DHA precursor | —d | —d | 2.9 | 8.7 |
DHA | 10 | 91 | 22.9 | 68.7 |
2,3-DKG | 6 | 119 | 6.1 | 18.3 |
a Repeatability conditions, n = 6.
b Replicate analyses, n = 3.
c Estimation not possible because analyte was below the limit of detection.
d Estimation not possible because compound is the intermediate in DHA-Q formation.